A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life

A Retrospective, Non-interventional, Single-center Study to Describe a Spanish Cohort of Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on HRQoL (Health-Related Quality of Life)

NCT06923124•Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

A retrospective, non-interventional, single-center study conducted in Spain, based on the collection of data from the medical histories of patients with Familial Mediterranean fever (FMF) diagnosed during childhood from January 2005 to December 2021. Data from the patients' medical records was collected retrospectively, from the time of diagnosis to the current moment of the patient's enrollment in the study. Patients had a minimum follow-up of 3 months after diagnosis.

Eligibility

Age

0 - 28 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients with FMF clinically and/or genetically diagnosed during childhood according to the site's clinical practice.
•2. Patients with at least 3 months of follow-up from the date of diagnosis, at the time of their enrollment in the study.

Exclusion Criteria

•1. Patients with autoinflammatory disease excluding FMF.
•2. Patients with recurrent fever of another etiology (infectious, tumor or other).

Locations (1)

Novartis

East Hanover, New Jersey, United States

Key Dates

Start Date

March 30, 2023

Primary Completion Date

May 28, 2024

Completion Date

May 28, 2024

Last Updated

April 11, 2025

Enrollment

ACTUAL participants

Conditions

Familial Mediterranean Fever

Mobile App-Based Infection Monitoring in Familial Mediterranean Fever

NCT07212764

Familial Mediterranean Fever (FMF )Infection+1 more

View study

COMPLETED

Assessment of Cardiorespiratory Fitness Using the PACER in Patients With Juvenile Idiopathic Arthritis and Familial Mediterranean Fever

NCT06697028

Juvenile Idiopathic ArthritisFamilial Mediterranean Fever+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Describe a Group of Spanish Patients With FMF and to Identify Suboptimally Treated Patients With Minimal Disease Activity and Its Impact on Quality of Life

Inclusion Criteria

Exclusion Criteria

Mobile App-Based Infection Monitoring in Familial Mediterranean Fever

Assessment of Cardiorespiratory Fitness Using the PACER in Patients With Juvenile Idiopathic Arthritis and Familial Mediterranean Fever

Caspase-1 Activity, IL-1beta, and IL-18 in Patients With FMF

Investigation of the Validity, Reliability and Responsiveness of the BETY-BQ in FMF

Assessment of microRNAs Role in Familial Mediterranean Fever FMF Pathophysiology

Clinical and Molecular Evaluation of Childern With Familial Meditterranean Fever and Their Siblings